Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs OROS-MPH on Executive Functions in ADHD
NCT02352051Phase 4Completed
- Sponsor
- Erciyes University
- Start
- Feb 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine group with Methylphenidate group (2 arms). Primary endpoints: Executive Functions measured by Wisconsin Card Sorting Test at 20 weeks, Executive Functions measured by Stroop Test TBAG Form at 20 weeks and 1 more. Started Feb 2014; status: completed.
02
Drugs
atomoxetinemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02352051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352051.